TURKISH JOURNAL OF PEDIATRICS, vol.63, no.6, pp.986-993, 2021 (SCI-Expanded)
Article / Article
TURKISH JOURNAL OF PEDIATRICS
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
atypical hemolytic uremic syndrome, treatment, plasma infusion, plasma exchange, outcome, CLINICAL CHARACTERISTICS, COMPLEMENT, MUTATIONS, ECULIZUMAB, MANAGEMENT, IMPACT, MICROANGIOPATHY, AHUS
Hacettepe University Affiliated:
Background. Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells. Plasma based therapy (PT) was the mainstay of the treatment for aHUS for many years until the introduction of therapies targeting blockage of the complement system. The aim of this study was to evaluate patients with aHUS who had been treated with plasma based therapies alone.